Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Assets (QoQ)Cash & Equivalents (QoQ)Cash from Operations (QoQ)Cash from Operations Growth (1y)EBIT (QoQ)EBIT Growth (1y)EBIT Margin (QoQ)EBIT Margin Growth (1y)EBITDA Margin (QoQ)EBITDA Margin Growth (1y)EBT (QoQ)EBT Growth (1y)EBT Margin (QoQ)EBT Margin Growth (1y)EPS (Basic) (QoQ)EPS (Basic) Growth (1y)EPS (Weighted Average and Diluted) (QoQ)EPS (Weighted Average and Diluted) Growth (1y)Enterprise Value (QoQ)FCF Margin (QoQ)FCF Margin Growth (1y)Free Cash Flow (QoQ)Free Cash Flow Growth (1y)Interest Coverage Ratio (QoQ)Net Cash Flow (QoQ)Net Cash Flow Growth (1y)Net Income (QoQ)Net Income Growth (1y)Net Income towards Common Stockholders (QoQ)Net Income towards Common Stockholders Growth (1y)Net Margin (QoQ)Net Margin Growth (1y)Operating Income (QoQ)Operating Income Growth (1y)Operating Margin (QoQ)Operating Margin Growth (1y)Profit After Tax (QoQ)Profit After Tax Growth (1y)Return on Assets (QoQ)Return on Capital Employed (QoQ)Return on Equity (QoQ)Return on Sales (QoQ)Return on Sales Growth (1y)Revenue (QoQ)Revenue Growth (1y)Shareholder's Equity (QoQ)
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Kairos Pharma (KAPA) Asset Utilization Ratio (2024 - 2025)
Generated on {Timestamp}
© BusinessQuant.com
Generated on {Timestamp}
Powered by
Historic Asset Utilization Ratio for Kairos Pharma (KAPA) over the last 2 years, with Q2 2025 value amounting to 13.62.
Peer Comparison
Historic Data
Download Data 🔒| Date | Value |
|---|---|